Eosinophilic Esophagitis
Eosinophilic esophagitis (EoE) is an allergic condition where eosinophils, a type of white blood cell, build up in the esophagus, leading to inflammation and difficulty swallowing.
Eosinophilic Esophagitis: BP1.7881 Treatment Study
We are testing a new medication, BP1.7881, for adults with eosinophilic esophagitis to see if it can improve their condition. The study will also look at how safe and well-tolerated the treatment is.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have symptoms related to EoE (like trouble swallowing, coughing, or vomiting) in the last 4 weeks?
- Have you been diagnosed with EoE (Eosinophilic Esophagitis) by a doctor?
- Are you currently pregnant or breastfeeding?
- Are you taking any immunosuppressive medications like Dupilumab, Mepolizumab, or Reslizumab?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Centre Hospitalier D'Antibes Juan Les Pins
Service de Gastroentérologie
Antibes, France
Centre Hospitalier Universitaire De Bordeaux
Service d’Hépato-Gastroentérologie et d’Oncologie Digestive
Canéjan, France
Hospices Civils De Lyon
Service d’Explorations Fonctionnelles Digestives
Villeurbanne, France
Sponsor: Bioprojet Pharma
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.